INHALATION ACADEMY
REFERENCES
Introductory Chapter
  1. World Health Organization. Chronic Respiratory Diseases. Available from: https://www.who.int/respiratory/en/.
  2. Cukic V, Lovre V, Dragisic D, et al. Asthma and chronic obstructive pulmonary disease (COPD)-differences and similarities. Materia socio-medica. 2012;24(2):100.
  3. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017;49(3).
  4. Quaderi S, Hurst J. The unmet global burden of COPD. Global health, epidemiology and genomics. 2018;3.
  5. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respiratory research. 2018;19(1):10.
  6. Laube B, Janssens H, De Jongh F. What thepulmonary specialist should know about the new inhalationtherapies. ERS/ISAM task force report. Eur Respir J. 2011;37(6):1308-31.
  7. Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respiratory medicine. 2017;124:6-14.
  8. Dekhuijzen PN, Lavorini F, Usmani OS. Patients' perspectives and preferences in the choice of inhalers: the case for Respimat((R)) or HandiHaler((R)). Patient Prefer Adherence. 2016;10:1561-72.
  9. Hanania NA, Braman S, Adams SG, et al. The role of inhalation delivery devices in COPD: perspectives of patients and health care providers. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2018;5(2):111.
  10. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. The Journal of Allergy and Clinical Immunology: In Practice. 2017;5(4):1071-81. e9.
  11. Ocakli B, Ozmen I, Tunçay EA, et al. a comparative analysis of errors in inhaler technique among COPD versus asthma patients. International journal of chronic obstructive pulmonary disease. 2018;13:2941.
  12. Westerik JA, Carter V, Chrystyn H, et al. Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. Journal of Asthma. 2016;53(3):321-9.
  13. Sanchis J, Gich I, Pedersen S, et al. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394-406.
  14. Braido F, Chrystyn H, Baiardini I, et al. “Trying, but failing”-the role of inhaler technique and mode of delivery in respiratory medication adherence. The Journal of Allergy and Clinical Immunology: In Practice. 2016;4(5):823-32.
  15. Stein SW, Thiel CG. The History of Therapeutic Aerosols: A Chronological Review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20-41.
Chapter 1
  1. Siafakas N, Vermeire P, Pride Na, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. European Respiratory Journal. 1995;8(8):1398-420
  2. Cukic V, Lovre V, Dragisic D, et al. Asthma and chronic obstructive pulmonary disease (COPD)-differences and similarities. Materia socio-medica. 2012;24(2):100.
  3. Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Canadian respiratory journal. 2018;2018.
  4. Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respiratory medicine. 2017;124:6-14.
  5. Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respiratory medicine. 2014;108(8):1195-203.
  6. Bosnic-Anticevich SZ. Continued innovation in respiratory care: the importance of inhaler devices. Tuberculosis and respiratory diseases. 2018;81(2):91-8.
  7. Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung deposition - What evidence is there? International Journal of Pharmaceutics. 2011;406(1):1-10.
  8. Dal Negro RW, Longo P, Ziani OV, et al. Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidisciplinary respiratory medicine. 2017;12(1):13.
  9. Capstick TG, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;6(1):91-101; quiz 2-3.
  10. Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique. International journal of chronic obstructive pulmonary disease. 2008;3(4):763.
  11. Pitcairn G, Reader S, Pavia D, et al. Deposition of Corticosteroid Aerosol in the Human Lung by Respimat® Soft Mist™ Inhaler Compared to Deposition by Metered Dose Inhaler or by Turbuhaler® Dry Powder Inhaler. Journal of Aerosol Medicine. 2005;18(3):264-72.
Chapter 2
  1. Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respiratory medicine. 2017;124:6-14.
  2. Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Canadian respiratory journal. 2018;2018.
  3. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Medical Devices (Auckland, NZ). 2011;4:145.
  4. Capstick TG, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;6(1):91-101; quiz 2-3.
  5. Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respiratory medicine. 2014;108(8):1195-203.
  6. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. American journal of respiratory and critical care medicine. 2005;172(12):1497-504.
  7. Dekhuijzen PNR, Lavorini F, Usmani OS. Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®). Patient Prefer Adherence. 2016;10:1561-72.
  8. Stein SW, Thiel CG. The History of Therapeutic Aerosols: A Chronological Review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20-41.
Chapter 3
  1. Cukic V, Lovre V, Dragisic D, et al. Asthma and chronic obstructive pulmonary disease (COPD)-differences and similarities. Materia socio-medica. 2012;24(2):100.
  2. Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respiratory medicine. 2017;124:6-14.
  3. Siafakas N, Vermeire P, Pride Na, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. European Respiratory Journal. 1995;8(8):1398-420.
  4. Dal Negro RW, Longo P, Ziani OV, et al. Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidisciplinary respiratory medicine. 2017;12(1):13.
  5. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Medical Devices (Auckland, NZ). 2011;4:145.
  6. Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ inhaler and pressurized metered dose inhalers. Journal of aerosol medicine. 2005;18(3):273-82.
  7. Tamura G. Comparison of the aerosol velocity of Respimat® soft mist inhaler and seven pressurized metered dose inhalers. Allergology International. 2015;64(4):390-2.
  8. Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respiratory medicine. 2014;108(8):1195-203.
  9. Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Canadian respiratory journal. 2018;2018.
  10. Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients' inhalation maneuvers. Respiratory medicine. 2016;118:65-75.
  11. Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18-31.
  12. Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113(4):957-63.
Chapter 4
  1. Bosnic-Anticevich SZ. Continued innovation in respiratory care: the importance of inhaler devices. Tuberculosis and respiratory diseases. 2018;81(2):91-8.
  2. Pohlmann G, Hohlfeld JM, Haidl P, et al. Assessment of the Power Required for Optimal Use of Current Inhalation Devices. Journal of aerosol medicine and pulmonary drug delivery. 2018;31(6):339-46.
  3. Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18-31.
  4. Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395-401.
  5. Everard ML, Devadason SG, Le Souëf PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respiratory Medicine. 1997;91(10):624-8.
  6. Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients' inhalation maneuvers. Respiratory medicine. 2016;118:65-75.
  7. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. European Respiratory Journal. 2008;31(1):78-83.
  8. Laube B, Janssens H, De Jongh F. What thepulmonary specialist should know about the new inhalationtherapies. ERS/ISAM task force report. Eur Respir J. 2011;37(6):1308-31.
  9. Bosnic-Anticevich SZ. Inhaler device handling: have we really started to address the problem? : Eur Respiratory Soc; 2017.
  10. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. European Respiratory Journal. 2017;49(2):1601794.
  11. Ocakli B, Ozmen I, Tunçay EA, et al. a comparative analysis of errors in inhaler technique among COPD versus asthma patients. International journal of chronic obstructive pulmonary disease. 2018;13:2941.
  12. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. The Journal of Allergy and Clinical Immunology: In Practice. 2017;5(4):1071-81. e9.
  13. Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respiratory medicine. 2014;108(8):1195-203.
  14. Melani AS, Bracci LS, Rossi M. Reduced Peak Inspiratory Effort through the Diskus® and the Turbuhaler® due to Mishandling is Common in Clinical Practice. Clinical Drug Investigation. 2005;25(8):543-9.
  15. Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Canadian respiratory journal. 2018;2018.
  16. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respiratory research. 2018;19(1):10.
  17. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Medical Devices (Auckland, NZ). 2011;4:145.
  18. Roche N, Dekhuijzen PR. The evolution of pressurized metered-dose inhalers from early to modern devices. Journal of aerosol medicine and pulmonary drug delivery. 2016;29(4):311-27.
  19. Stein SW, Thiel CG. The History of Therapeutic Aerosols: A Chronological Review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20-41.
Chapter 5
  1. Myers L, Murray RK. Overcoming Health Literacy Barriers to Improve Asthma Inhaler Therapy Adherence. Annals of the American Thoracic Society. 2019;16(2):182-186.
  2. Poureslami I, Nimmon L, Rootman I, Fitzgerald MJ. Health literacy and chronic disease management: drawing from expert knowledge to set an agenda. Health promotion international. 2017;32(4):743-754.
  3. Hersh L, Salzman B, Snyderman D. Health Literacy in Primary Care Practice. American family physician. 2015;92(2):118-124.
  4. Stellefson ML, Shuster JJ, Chaney BH, et al. Web-based Health Information Seeking and eHealth Literacy among Patients Living with Chronic Obstructive Pulmonary Disease (COPD). Health communication. 2018;33(12):1410-1424.
  5. Metting E, Schrage AJ, Kocks JW, Sanderman R, van der Molen T. Assessing the Needs and Perspectives of Patients With Asthma and Chronic Obstructive Pulmonary Disease on Patient Web Portals: Focus Group Study. JMIR formative research. 2018;2(2):e22.
  6. Kale MS, Federman AD, Krauskopf K, et al. The Association of Health Literacy with Illness and Medication Beliefs among Patients with Chronic Obstructive Pulmonary Disease. PloS one. 2015;10(4):e0123937.
  7. World Health Organization. Health Promotion Track 2: health literacy and health behaviour.
    Available at: http://www.who.int/healthpromotion/conferences/7gchp/track2/en/ (accessed 4 July 2019).
  8. Koh HK, Rudd RE. The Arc of Health Literacy. Jama. 2015;314(12):1225-1226.
  9. Sorensen K, Pelikan JM, Rothlin F, et al. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). European journal of public health. 2015;25(6):1053-1058.
  10. Puente-Maestu L, Calle M, Rodriguez-Hermosa JL, et al. Health literacy and health outcomes in chronic obstructive pulmonary disease. Respiratory medicine. 2016;115:78-82.
  11. Soones TN, Lin JL, Wolf MS, et al. Pathways linking health literacy, health beliefs, and cognition to medication adherence in older adults with asthma. The Journal of allergy and clinical immunology. 2017;139(3):804-809.
  12. O'Conor R, Muellers K, Arvanitis M, et al. Effects of health literacy and cognitive abilities on COPD self-management behaviors: A prospective cohort study. Respiratory medicine. 2019.
  13. Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Annals of internal medicine. 2011;155(2):97-107.
  14. Baker DW, Wolf MS, Feinglass J, Thompson JA, Gazmararian JA, Huang J. Health literacy and mortality among elderly persons. Archives of internal medicine. 2007;167(14):1503-1509.
  15. Omachi TA, Sarkar U, Yelin EH, Blanc PD, Katz PP. Lower health literacy is associated with poorer health status and outcomes in chronic obstructive pulmonary disease. Journal of general internal medicine. 2013;28(1):74-81.
  16. Stellefson M, Paige SR, Alber JM, et al. Association Between Health Literacy, Electronic Health Literacy, Disease-Specific Knowledge, and Health-Related Quality of Life Among Adults With Chronic Obstructive Pulmonary Disease: Cross-Sectional Study. Journal of medical Internet research. 2019;21(6):e12165.
  17. Beatty CR, Flynn LA, Costello TJ. The Impact of Health Literacy Level on Inhaler Technique in Patients With Chronic Obstructive Pulmonary Disease. Journal of pharmacy practice. 2017;30(1):25-30.
Chapter 6
  1. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respiratory research. 2018;19(1):10.
  2. Sanchis J, Gich I, Pedersen S. Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? Chest. 2016;150(2):394-406.
  3. Kocks JWH, Chrystyn H, van der Palen J, et al. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. NPJ primary care respiratory medicine. 2018;28(1):43.
  4. Levy ML, Dekhuijzen PN, Barnes PJ, et al. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ primary care respiratory medicine. 2016;26:16017.
  5. Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. The journal of allergy and clinical immunology In practice. 2017;5(4):1071-1081.e1079.
  6. Dekhuijzen PN, Vincken W, Virchow JC, et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respiratory medicine. 2013;107(12):1817-1821.
  7. Braido F, Chrystyn H, Baiardini I, et al. "Trying, But Failing" - The Role of Inhaler Technique and Mode of Delivery in Respiratory Medication Adherence. The journal of allergy and clinical immunology In practice. 2016;4(5):823-832.
  8. Newman SP. Inhaler treatment options in COPD. European Respiratory Review. 2005;14(96):102-108.
Chapter 7
  1. Takaku Y, Kurashima K, Ohta C, et al. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respiratory medicine. 2017;123:110-115.
  2. Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients' inhalation maneuvers. Respiratory medicine. 2016;118:65-75.
  3. Roman-Rodriguez M, Metting E, Gacia-Pardo M, Kocks J, van der Molen T. Wrong inhalation technique is associated to poor asthma clinical outcomes. Is there room for improvement? Current opinion in pulmonary medicine. 2019;25(1):18-26.
  4. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respiratory medicine. 2011;105(6):930-938.
  5. Axtell S, Haines S, Fairclough J. Effectiveness of Various Methods of Teaching Proper Inhaler Technique. Journal of pharmacy practice. 2017;30(2):195-201.
  6. Bosnic-Anticevich SZ, Sinha H, So S, Reddel HK. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. The Journal of asthma : official journal of the Association for the Care of Asthma. 2010;47(3):251-256.
  7. Press VG, Arora VM, Shah LM, et al. Teaching the use of respiratory inhalers to hospitalized patients with asthma or COPD: a randomized trial. Journal of general internal medicine. 2012;27(10):1317-1325.
  8. Muller T, Muller A, Hubel C, et al. Optimizing inhalation technique using web-based videos in obstructive lung diseases. Respiratory medicine. 2017;129:140-144.
  9. van der Palen J, Klein JJ, Kerkhoff AH, van Herwaarden CL, Seydel ER. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient education and counseling. 1997;32(1 Suppl):S87-95.
  10. Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. The European respiratory journal. 2018;51(1).
  11. Sulaiman I, Cushen B, Greene G, et al. Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine. 2017;195(10):1333-1343.
  12. Press VG, Arora VM, Trela KC, et al. Effectiveness of Interventions to Teach Metered-Dose and Diskus Inhaler Techniques. A Randomized Trial. Annals of the American Thoracic Society. 2016;13(6):816-824.
  13. Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. The Journal of allergy and clinical immunology. 2007;119(6):1537-1538.
Chapter 8
  1. Vrijens B, Dima AL, Van Ganse E, et al. What We Mean When We Talk About Adherence in Respiratory Medicine. The journal of allergy and clinical immunology In practice. 2016;4(5):802-812.
  2. Dekhuijzen R, Lavorini F, Usmani OS, van Boven JFM. Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here? The journal of allergy and clinical immunology In practice. 2018;6(3):785-793.
  3. Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respiratory medicine. 2013;107(10):1481-1490.
  4. van Boven JFM, Lavorini F, Dekhuijzen PNR, Blasi F, Price DB, Viegi G. Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. The European respiratory journal. 2017;49(5).
  5. World Health Organization. Adherence to long-term therapies: evidence for action. 2003.
  6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Available from: www.ginasthma.org.
  7. Vetrano DL, Bianchini E, Onder G, et al. Poor adherence to chronic obstructive pulmonary disease medications in primary care: Role of age, disease burden and polypharmacy. Geriatrics & gerontology international. 2017;17(12):2500-2506.
  8. van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respiratory medicine. 2014;108(1):103-113.
Chapter 9
  1. Dekhuijzen, P.N., et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respiratory medicine 107, 1817-1821 (2013).
  2. Kaplan, A. & Price, D. Matching Inhaler Devices with Patients: The Role of the Primary Care Physician. Canadian respiratory journal 2018, 9473051 (2018).